The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
The initiative was announced at World Hypertension Congress, Chennai
The initiative aims to empower individuals to take proactive steps towards monitoring their health
Enables millions of Indians to monitor their vitals without the need of any additional device
Labetalol hydrochloride injection USP is indicated for the control of blood pressure in severe hypertension.
Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
Clears major obesity endpoints at 80 weeks
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
